2023 international evidence-based guideline pcos glp-1 receptor agonist Evidence‐Based Polycystic Ovary Syndrome Update: Insights From a Systematic Review and Meta‐Analysis on Elevated Clinical Cardiovascular Disease in Polycystic Ovary Syndrome Efficacy of GLP-1 Receptor Agonists
Description
Ablation of hindbrain catecholamine neurons using anti-dopamine--hydroxylase-saporin (DSAP) blunts the ability of exendin-4 to increase corticosterone secretion but interestingly potentiates the food intake inhibition by exendin-4 [819]
and reducing stellate cell activation, potentially reducing their fibrotic response to liver injury [37]
Data from semaglutide discontinuation studies shows that approximately two-thirds of lost weight returns within one year of cessation
Since then, the science of GLP-1s has continued to improve
JAMA (2016) 315:2424
(Seoul.) 36 , 647660 (2021)
